2020 review – Pharma’s progress outside of COVID-19
pharmaphorum
DECEMBER 23, 2020
The company’s menopause drug NT-814 is heading for phase 3 development in 2021 following a mid-stage trial readout. NT-814 is a non-hormonal drug that works on the neurokinin (NK) 1,3 receptor antagonist, thus treating the vasomotor symptoms associated with the menopause. Rare disease progress.
96 
Let's personalize your content